Celator's CPX-351 bests standard of care in AML study
EWING, N.J.—Celator Pharmaceuticals Inc. has released final induction response rate results (complete remission plus complete remission with incomplete hematologic recovery, or CR+CRi) in its Phase 3 study of CPX-351 liposome injection compared with the standard-of-care regimen, or 7+3 (conventional cytarabine and daunorubicin treatment), in patients with untreated high-risk acute myeloid leukemia (AML). Celator partnered with the Leukemia & Lymphoma Society in developing CPX-351. CPX-351 treatment resulted in a relative improvement in induction response rate of 43.2 percent—47.7 percent for CPX-351 vs. 33.3 percent for the 7+3 regimen.
Dr. Jeffrey Lancet, senior member and chief of the Leukemia/Myelodysplasia Program at Moffitt Cancer Center and lead investigator on the study, noted, “The results are encouraging because this is the third randomized study in which CPX- 351 outperformed the control arm of cytarabine plus an anthracycline in overall response rate.”